GeneHealth - Your precision medicine

Charcot-marie-tooth Disease Dominant Intermediate E

Disease Details

Family Health Simplified

Buy Membership

Description: Charcot-Marie-Tooth disease, dominant intermediate E, is a type of inherited peripheral neuropathy characterized by progressive muscle weakness and atrophy, primarily affecting the lower extremities and hands, along with sensory loss.

One-sentence description: Charcot-Marie-Tooth disease, dominant intermediate E, is an inherited disorder leading to progressive muscle weakening and sensory loss in the limbs.
Type: Autosomal dominant
Signs And Symptoms: **Signs and Symptoms:**

Charcot-Marie-Tooth Disease Dominant Intermediate E (CMT-DIE) is a subtype of Charcot-Marie-Tooth disease, a hereditary neuropathy. Signs and symptoms of CMT-DIE typically include:

1. **Muscle Weakness:** Progressive weakness especially in the distal muscles of the legs and hands.
2. **Atrophy:** Wasting of muscles in the feet, lower legs, hands, and forearms.
3. **Foot Deformities:** High arches (pes cavus) or flat feet.
4. **Gait Problems:** Difficulty walking, foot drop, and an altered gait pattern.
5. **Neuropathic Pain:** Pain or discomfort due to nerve damage.
6. **Sensory Loss:** Reduced ability to feel pain, temperature changes, and touch, primarily in the limbs.
7. **Reduced Reflexes:** Diminished or absent deep tendon reflexes.
8. **Fine Motor Challenges:** Difficulty with tasks that require manual dexterity, such as buttoning shirts or writing.

Early onset typically occurs in adolescence or early adulthood, but the severity and progression can vary significantly among individuals.
Prognosis: Charcot-Marie-Tooth disease, type dominant intermediate E (CMT-DIE), is a subtype of Charcot-Marie-Tooth disease, a group of inherited peripheral neuropathies. Here are key points about the prognosis of CMT-DIE:

1. **Progression**: The disease typically progresses slowly. Symptoms can vary widely even among family members.
2. **Life Expectancy**: CMT-DIE generally does not affect life expectancy, but it can significantly impact quality of life due to muscle weakness and atrophy.
3. **Motor and Sensory Impairment**: Individuals may experience progressive motor and sensory impairment predominantly in the lower limbs first, and sometimes in the upper limbs as well.
4. **Disability**: Many individuals remain ambulatory throughout life, but some may require mobility aids over time.
5. **Therapy and Management**: Physical therapy, occupational therapy, and sometimes orthopedic interventions like braces or surgery can help manage symptoms and improve function.

Regular follow-up with healthcare providers specializing in neuromuscular diseases is important for managing CMT-DIE.
Onset: Charcot-Marie-Tooth Disease, Dominant Intermediate E (CMTDIE) typically has an onset in adolescence or early adulthood.
Prevalence: The prevalence of Charcot-Marie-Tooth disease (CMT) as a whole is estimated to be about 1 in 2,500 people. However, specific prevalence data for Charcot-Marie-Tooth disease, dominant intermediate E (CMT-DI-E), is not well-documented, making it challenging to provide a precise figure. Generally, intermediate forms of CMT are less common than the more prevalent types like CMT1 and CMT2.
Epidemiology: Charcot-Marie-Tooth disease dominant intermediate E (CMT-DIE) is a rare subtype of Charcot-Marie-Tooth disease, a group of inherited peripheral neuropathies. The epidemiology specifics for this rare subtype are not well-documented due to its rarity. The broader category of Charcot-Marie-Tooth disease affects approximately 1 in 2,500 people.
Intractability: Charcot-Marie-Tooth disease, dominant intermediate E (CMT-DIE), like other forms of Charcot-Marie-Tooth disease, is generally considered intractable in terms of a cure. There is currently no cure for CMT-DIE; however, there are treatments available to manage symptoms and improve quality of life. These treatments may include physical therapy, occupational therapy, orthopedic devices, and sometimes surgical interventions to address severe deformities or complications. Research is ongoing to find more effective treatments and potential cures.
Disease Severity: Charcot-Marie-Tooth disease dominant intermediate E (CMT-DIE) is a subtype of Charcot-Marie-Tooth disease. The severity of CMT can vary significantly among individuals. In general, it can range from mild to severe, impacting mobility and quality of life. Some individuals may experience mild symptoms and maintain almost normal function, while others may have significant disability requiring assistive devices.

Regarding "nan," it appears to be a placeholder for missing data (not a number). Therefore, no further specific information can be provided on that aspect without additional context.
Healthcare Professionals: Disease Ontology ID - DOID:0110205
Pathophysiology: Charcot-Marie-Tooth disease dominant intermediate E (CMT-DIE) is a subtype of Charcot-Marie-Tooth disease, a group of inherited neuropathies. The pathophysiology involves mutations in the YARS gene, which encodes tyrosyl-tRNA synthetase. This enzyme is pivotal in the translation process during protein synthesis. The mutations affect axonal integrity and Schwann cell function, leading to a combination of demyelination and axonal loss. This results in progressive muscle weakness and atrophy, predominantly in the distal limbs, along with sensory deficits. Nerve conduction studies typically reveal intermediate velocities, reflecting the mixed axonal/demyelinating pathology.
Carrier Status: Charcot-Marie-Tooth Disease Dominant Intermediate E (CMT-DIE) is an inherited neuropathy. This form of the disease follows an autosomal dominant inheritance pattern. Therefore, there isn't a traditional "carrier" status as seen in recessive disorders. Individuals with one copy of the mutated gene will exhibit symptoms of the disease. Both males and females are affected equally since it is not linked to sex chromosomes.
Mechanism: Charcot-Marie-Tooth disease dominant intermediate E (CMT-DIE) is a subtype of Charcot-Marie-Tooth disease (CMT), a group of inherited neuropathies characterized by progressive muscle weakness and atrophy, primarily affecting the peripheral nerves.

**Mechanism:**
CMT-DIE is caused by mutations in specific genes that lead to dysfunctional proteins involved in maintaining the structure and function of peripheral nerves. This subtype exhibits intermediate nerve conduction velocities, which means that the nerve conduction speed is between the ranges observed in demyelinating forms (slower) and axonal forms (faster) of CMT.

**Molecular Mechanisms:**
1. **Gene Mutations:** CMT-DIE is associated with mutations in genes such as DNM2 (dynamin 2), INF2 (inverted formin, FH2, and WH2 domain containing), or GDAP1 (ganglioside-induced differentiation-associated protein 1), among others.
2. **Protein Dysfunction:** These mutations lead to alterations in proteins that are essential for:
- **Cytoskeletal Dynamics:** DNM2 and INF2 mutations disrupt the organization and dynamics of the cytoskeleton, affecting processes like vesicle trafficking, endocytosis, and cell shape.
- **Mitochondrial Function:** GDAP1 mutations impact mitochondrial dynamics and function, contributing to cellular energy deficits and increased susceptibility to cellular stress.
3. **Axonal Transport:** The disruption in these proteins' normal functioning impairs axonal transport mechanisms, crucial for nutrient and organelle distribution, leading to axon degeneration and subsequent muscle atrophy and weakness.

Overall, the molecular mechanisms involve a combination of impaired cellular structures and functions, leading to the progressive neuropathy seen in CMT-DIE.
Treatment: Charcot-Marie-Tooth Disease, Dominant Intermediate E (CMTDIE) is currently managed symptomatically, as there is no cure. Treatment approaches typically focus on:

1. **Physical Therapy**: To strengthen and stretch muscles, improve mobility, and reduce stiffness.
2. **Occupational Therapy**: To assist with daily activities and suggest adaptive devices.
3. **Orthotic Devices**: Such as braces, splints, or custom-made shoes to improve walking and prevent injury.
4. **Medications**: For pain management, including non-steroidal anti-inflammatory drugs (NSAIDs) and sometimes neuropathic pain medications.
5. **Surgery**: In severe cases, orthopedic surgery might be considered to correct deformities or improve function.

Regular follow-ups with a multidisciplinary team including neurologists, physiotherapists, and occupational therapists are essential to tailor the treatment plan to the individual’s needs.
Compassionate Use Treatment: Charcot-Marie-Tooth Disease Dominant Intermediate E (CMT-DI-E) currently lacks widespread established treatments specifically approved for this subtype. However, several experimental and off-label treatments are being explored:

1. **Gene Therapy**: Researchers are investigating gene therapies to correct or compensate for the genetic mutations causing the disease.

2. **Neurotrophic Factors**: Experimental use of neurotrophic factors, such as neurotrophin-3 (NT-3), aims to promote nerve growth and repair.

3. **PXT3003**: An experimental drug cocktail containing baclofen, naltrexone, and D-sorbitol has shown promise in clinical trials for certain CMT types and may offer potential benefits.

4. **Ascorbic Acid (Vitamin C)**: Some studies have suggested high-dose ascorbic acid might help delay progression, though results are mixed and aren't universally endorsed.

5. **Charcot-Marie-Tooth Trials**: Participation in clinical trials investigating new therapies could provide access to cutting-edge treatments not yet available widely.

6. **Off-Label Medications**: Drugs like gabapentin or pregabalin, typically used for neuropathic pain, might be prescribed to alleviate some symptoms associated with CMT-DI-E.

Always consult a healthcare provider to discuss potential treatments, their risks, benefits, and appropriateness for individual cases.
Lifestyle Recommendations: Charcot-Marie-Tooth Disease Dominant Intermediate E (CMT-DIE) is a subtype of Charcot-Marie-Tooth disease, a genetic disorder affecting peripheral nerves. For managing this condition, consider the following lifestyle recommendations:

1. **Regular Physical Therapy**: Engage in low-impact exercises and physical therapy to maintain muscle strength and flexibility. Activities like swimming or cycling can be beneficial.

2. **Ergonomic Adjustments**: Use ergonomic tools and adaptive devices to assist with daily activities and reduce strain on muscles and nerves.

3. **Foot Care**: Pay close attention to foot health. Wear well-fitted orthopedic shoes and consider custom orthotics to provide proper support and reduce the risk of foot injuries.

4. **Diet and Nutrition**: Maintain a balanced and nutritious diet to support overall health and muscle function.

5. **Avoid Prolonged Inactivity**: Staying active within comfort limits is important to prevent muscle atrophy.

6. **Pain Management**: Utilize prescribed medications or non-drug therapies like massage and heat/cold treatment to manage pain.

7. **Regular Monitoring**: Have regular check-ups with healthcare providers, including neurologists and physiotherapists, to monitor disease progression and adjust management plans accordingly.

8. **Support Systems**: Engage with support groups and mental health professionals to manage emotional and psychological challenges associated with chronic disease.

Implementing these lifestyle changes can help manage symptoms and improve the quality of life for individuals with CMT-DIE.
Medication: Currently, there is no specific medication approved to treat Charcot-Marie-Tooth Disease Dominant Intermediate E (CMTDIE). Treatment typically focuses on managing symptoms and may include physical therapy, occupational therapy, orthopedic devices, and pain management. Consult with a healthcare provider for personalized care and the latest treatment options.
Repurposable Drugs: Currently, there are no specific repurposable drugs widely recognized for Charcot-Marie-Tooth disease, dominant intermediate E (CMTDIE). Treatment primarily focuses on symptom management through physical therapy, orthopedic devices, pain management, and sometimes surgery. Researchers are actively investigating potential therapeutic options, so it's essential to stay updated on new developments and clinical trials specific to CMTDIE. Always consult a healthcare professional for personalized medical advice.
Metabolites: Charcot-Marie-Tooth disease dominant intermediate E (CMT-DIE) is characterized by mutations in the genes that can affect various metabolic pathways. However, specific information on metabolites directly linked to this subtype of the disease is limited in the literature. Generally, one might consider that nerve function and health could be influenced by common metabolites involved in oxidative stress, mitochondrial function, and lipid metabolism, which are often areas of concern in broader types of neuropathies.

If detailed metabolite profiles are needed, they typically require specific biochemical analyses and might vary depending on individuals and specific genetic mutations.
Nutraceuticals: Charcot-Marie-Tooth disease dominant intermediate E (CMTDIE) does not currently have specific nutraceuticals proven to treat or cure the condition. Nutritional support can be beneficial for overall health and may help manage symptoms, but any use of nutraceuticals should be discussed with a healthcare provider to ensure safety and appropriateness for the individual's condition.
Peptides: Charcot-Marie-Tooth disease dominant intermediate E is a subtype of Charcot-Marie-Tooth disease, which is a group of inherited disorders that cause peripheral neuropathy. Intermediate forms generally show symptoms and nerve conduction velocities that are between those seen in typical demyelinating and axonal types. As of now, specific peptide treatments for this subtype are not well-documented, and the condition is primarily managed through supportive and symptomatic treatments like physical therapy and orthotic devices. Research in nanotechnology for targeted therapy in neuropathies is evolving, but specific nanomedical treatments for this subtype have not been established.